These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 8619577

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa.
    Mouneimné H, Robert J, Jarlier V, Cambau E.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):62-6. PubMed ID: 9869566
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ.
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [Abstract] [Full Text] [Related]

  • 9. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T, Yasuda M, Nakano M, Ozeki S, Kanematsu E, Nishino Y, Ishihara S, Kawada Y.
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [Abstract] [Full Text] [Related]

  • 10. Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones.
    Takenouchi T, Sakagawa E, Sugawara M.
    Antimicrob Agents Chemother; 1999 Feb; 43(2):406-9. PubMed ID: 9925546
    [Abstract] [Full Text] [Related]

  • 11. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.
    Jalal S, Wretlind B.
    Microb Drug Resist; 1998 Feb; 4(4):257-61. PubMed ID: 9988043
    [Abstract] [Full Text] [Related]

  • 12. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T, Tanaka M, Yamaguchi A, Sato K.
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [Abstract] [Full Text] [Related]

  • 13. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J, Bachoual R, Ouabdesselam S, Boudjadja A, Soussy CJ.
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM, Lawrence JM, Josty IC, Hopewell R, Margerrison EE, Cullen ME.
    Am J Med; 1989 Nov 30; 87(5A):2S-8S. PubMed ID: 2574005
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.
    Gimeno C, Navarro D, Savall F, Millás E, Farga MA, Garau J, Cisterna R, García-de-Lomas J.
    Eur J Clin Microbiol Infect Dis; 1996 Jan 30; 15(1):82-5. PubMed ID: 8641311
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid.
    Cambau E, Bordon F, Collatz E, Gutmann L.
    Antimicrob Agents Chemother; 1993 Jun 30; 37(6):1247-52. PubMed ID: 8392306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.